Podcasts

Biosimilars Regulatory Roundup for September 2023—Podcast Edition

October 1st 2023

Podcast

On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.

Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?

September 17th 2023

Podcast

On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.

Biosimilars Business Roundup For August 2023—Podcast Edition

September 5th 2023

Podcast

On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.

How Streamlining Development Can Save the US Biosimilar Industry

August 20th 2023

Podcast

On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.

Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment

July 16th 2023

Podcast

Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.

Biosimilars Business Roundup for June 2023—Podcast Edition

July 2nd 2023

Podcast

On this episode, we’re going to be recapping some of the biggest stories in the business space regarding biosimilars, including adalimumab preparation, partnerships for commercialization, and more.

Biosimilars Immunology Roundup for May 2023—Podcast Edition

June 4th 2023

Podcast

On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.

Biosimilars Rheumatology Roundup for April 2023—Podcast Edition

April 30th 2023

Podcast

On this episode of Not So Different, we recap some of the main news in April regarding biosimilars used to treat rheumatic conditions, including some progressions and some setbacks as well as research on nonmedical switching from originators to biosimilars.

Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars

April 16th 2023

Podcast

What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.

Biosimilars Policy Roundup for March 2023—Podcast Edition

April 2nd 2023

Article

On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.